Brief: Mirati Therapeutics Provides Update On Regulatory Review In EU Of Krazati (Adagrasib

Mirati Therapeutics

21/07/2023 11:20

July 21 (Reuters) - Mirati Therapeutics Inc  MRTX.O :
    * MIRATI THERAPEUTICS - PROVIDES UPDATE ON REGULATORY REVIEW
IN
EUROPEAN UNION OF KRAZATI (ADAGRASIB) FOR TREATMENT OF ADVANCED
NSCLC WITH KRAS(G12C) MUTATION
    * MIRATI THERAPEUTICS - EMA'S DECISION WILL HAVE NO IMPACT
ON ANY
OF CO'S CLINICAL TRIALS
    * MIRATI THERAPEUTICS - WILL CONTINUE TO WORK CLOSELY WITH
EMA AND
CHMP TO BRING ADAGRASIB TO ELIGIBLE PATIENTS
    * MIRATI THERAPEUTICS - DISAGREES WITH THE OPINION OF EMA
AND
INTENDS TO REQUEST FORMAL RE-EXAMINATION
    * MIRATI THERAPEUTICS-CHMP ISSUED NEGATIVE OPINION ON
CONDITIONAL
MAA FOR KRAZATI FOR TREATMENT OF  KRAS(G12C)-MUTATED ADVANCED
NON-SMALL CELL LUNG CANCER
    * MIRATI THERAPEUTICS - STUDY ENROLLMENT FOR KRYSTAL-12 IS
PROGRESSING AS EXPECTED
    * MIRATI THERAPEUTICS INC- PROGRESSION-FREE SURVIVAL AND
INTERIM
OVERALL SURVIVAL RESULTS ARE ANTICIPATED IN THE FIRST HALF OF
2024

Source text for Eikon:  ID: 
Further company coverage:  MRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))